Anti-SPARC Antibody, clone 5N19 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 5N19 is a ZooMAb^® recombinant rabbit monoclonal antibody that specifically detects SPARC. It targets an epitope within 24 amino acids from the C-terminal half.

KLH-conjugated linear peptide corresponding to 24 amino acids from the C-terminal half of human SPARC.

Quality Control Testing

Evaluated by Western Blotting in C6 cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected SPARC in C6 cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected His-tagged, recombinant fragment of human SPARC.

Flow Cytometry Analysis: 1 µg from a representative lot detected SPARC in one million Human umbilical vein endothelial cells (HUVEC).

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected SPARC in Human umbilical vein endothelial cells (HUVEC).

Immunohistochemistry (Paraffin) Analysis: A 1:1000 dilution from a representative lot detected SPARC in human kidney tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound SPARC peptide with at least ten million-fold (10,000,000X) higher affinity than with non-specific control peptide.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Basement-membrane protein 40 (BM-40) (UniProt: P09486; also known as Osteonectin, ON, Secreted protein acidic and rich in cysteine) is encoded by the SPARC (also known as ON) gene (Gene ID: 6678) in human. It is a matrix-associated protein that elicits changes in cell shape, inhibits cell-cycle progression, and influences the synthesis of extracellular matrix (ECM). It also binds to calcium, copper, several types of collagen, albumin, thrombospondin, PDGF and cell membranes. SPARC protein has an acidic domain that binds 5 to 8 Ca2+ with a low affinity, a cysteine-rich domain, and an EF-hand loop that binds a Ca2+ ion with a high affinity. The protein is synthesized with a signal peptide (aa 1-17), which is subsequently cleaved off to produce the mature form (aa 18-303). It is expressed at high levels in tissues undergoing morphogenesis, remodeling and wound repair. SPARC protein is primarily secreted into the extracellular space, where it interacts with the extracellular matrix. Although, being highly valued in non-nerve tissues, studies in both cell and animal models have revealed that SPARC family proteins may also continue to play a vital role in central nervous system (CNS) diseases and development. SPARC has also been demonstrated as an important player in the context of obesity, diabetes, and fatty liver disease including advanced hepatic fibrosis and hepatocellular carcinoma. Evidence in murine and human samples indicates that SPARC is involved in adipogenesis, cellular metabolism, extracellular matrix modulation, glucose and lipid metabolism. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Chen, S., et al. (2020). Brain Research Bulletin. 163; 178-189; Atorrasagasti, C., et al. (2023). Journal of Physiology and Biochemistry. 79; 815 831).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.